{
    "doi": "https://doi.org/10.1182/blood.V118.21.5302.5302",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2048",
    "start_url_page_num": 2048,
    "is_scraped": "1",
    "article_title": "Long-Term Use of Deferiprone Enhances Significantly the Left Ventricular Ejection Function in Thalassemia Major ",
    "article_date": "November 18, 2011",
    "session_type": "Thalassemia and Globin Gene Regulation",
    "topics": [
        "cooley's anemia",
        "deferiprone",
        "left ventricle",
        "deferoxamine",
        "iron",
        "adverse event",
        "blood transfusion",
        "brachial plexus neuritis",
        "cardiac arrhythmia",
        "chelating agents"
    ],
    "author_names": [
        "Aurelio Maggio, M.D.",
        "Marcello Capra, M.D.",
        "Liana Cuccia, M.D.",
        "Francesco Gagliardotto, M.D.",
        "Paolo Rigano, M.D.",
        "Giusi Calvaruso, M.D.",
        "Lorella Pitrolo, M.D.",
        "Luciano Prossomariti, M.D.",
        "Aldo Filosa, M.D.",
        "Maria Antonietta Romeo, M.D.",
        "Vincenzo Caruso, M.D.",
        "Crocetta Argento, M.D.",
        "Calogera Gerardi, M.D.",
        "Saveria Campisi, M.D.",
        "Pietro Violi, M.D.",
        "Paolo Cianciulli, M.D.",
        "Michele Rizzo, M.D.",
        "Domenico Giuseppe D'Ascola, M.D.",
        "Ketty Perrotta, M.D.",
        "Carmelo Fidone, M.D.",
        "Gaetano Roccamo, M.D.",
        "Antonella Carollo, M.D.",
        "Luciana Rigoli, M.D.",
        "Francesca Valeria Commendatore, M.D.",
        "Roberto Giugno, M.D.",
        "Rossellina Rosso, M.D.",
        "Rocca Cingari, M.D.",
        "Maria Concetta Galati, M.D.",
        "Antonella Quarta, M.D.",
        "Angela Ciancio, M.D.",
        "Angela Vitrano, PhD"
    ],
    "author_affiliations": [
        [
            "UOC Ematologia II, Ospedali Riuniti \u201cVilla Sofia-Cervello\u201d, Palermo, Italy, Palermo, Italy, "
        ],
        [
            "Unita\u0300 Operativa Complessa VII Pediatria per le Emopatie Ereditarie, Centro di Prevenzione Diagnosi e Cura della Talassemia, P.O.Ospedale Civico e Benfratelli, Palermo, KY, Italy, "
        ],
        [
            "P.O.Ospedale Civico e Benfratelli, Palermo, Italia, "
        ],
        [
            "PO Civico e Benfratelli,Palermo, Italia, "
        ],
        [
            "Hematology and Oncology, Ospedali Riuniti Villa Sofia- Cervello, Palermo, Italy, "
        ],
        [
            "AO Villa Sofia-V. Cervello, Palermo,Italia, "
        ],
        [
            "AO Villa Sofia-V. Cervello, Palermo,Italia, "
        ],
        [
            "Centro Regionale per la Cura delle Microcitemie, Azienda Ospedaliera Cardarelli, Napoli, Italia, "
        ],
        [
            "Unita\u0300 Operativa Complessa Pediatria, Azienda Ospedaliera Cardarelli, Napoli, Italia, "
        ],
        [
            "Dipartimento Pediatria, Azienda Policlinico, Catania, Italy, "
        ],
        [
            "Unita\u0300 Operativa Dipartimentale Talassemia, P.O. \u201cS. Luigi-Curro\u0300\u201d - ARNAS Garibaldi, Catania, Italy, "
        ],
        [
            "Azienda Ospedaliera San Giovanni di Dio, Agrigento, Italia, "
        ],
        [
            " P.O.\u201cGiovanni Paolo II\u201d Sciacca Distretto AG2 ASP Agrigento, Sciacca, Italy, "
        ],
        [
            "Unita\u0300 Operativa Semplice Centro Microcitemia, Azienda Ospedaliera Umberto I, Siracusa, Italia, "
        ],
        [
            "Centro della Microcitemia, San Giovanni Rotondo, Foggia, Italia, "
        ],
        [
            "Centro Talassemie, Ospedale \u201cSant'Eugenio Papa\u201d, Roma, Italy, "
        ],
        [
            "Rep. di Ematologia, Ospedale \u201cSant'Elia\u201d, Caltanisetta, Italy, "
        ],
        [
            "UO Microcitemie, AO Bianchi-Melacrino-Morelli, Reggio Calabria, Italy, "
        ],
        [
            "Osp. \u201cV. Emanuele III\u201d, Serv. Talassemia, Gela, "
        ],
        [
            "Unita\u0300 Operativa Complessa Centro Trasfusionale, Azienda Ospedaliera Maria Paterno\u0300 Arezzo, Ragusa, Italia, "
        ],
        [
            "Unita\u0300 di Prevenzione e Cura delle Mictrocitemie, Ospedale \u201cCivile\u201d, S. Agata di Militello (ME), Italy, "
        ],
        [
            "Servizio Talassemia-U.O. Pediatria Talassemia, Az. Osp. \u201cSant'Antonio abate\u201d, Trapani, "
        ],
        [
            "Dip. Scienze Pediatriche - U.O. Genetica ed Immunologia Pediatrica Messina,Italia, "
        ],
        [
            "ASL. 8 Siracusa Ospedale di Lentini-U.O. \u201cTalassemia\u201d Lentini, Siracusa, Italia, "
        ],
        [
            "Azienda Ospedaliera \u201cGravina e Santo Pietro\u201dU.O. \u201cTalassemia\u201d Caltagirone, Italia, "
        ],
        [
            "P.O. \u201cS. Bambino\u201d U.O. Servizio di Talassemia,Catania,Italia, "
        ],
        [
            "A.O. Ferrarotto U.O. Ematologia,Catania,Italia, "
        ],
        [
            "Azienda Ospedaliera Pugliese Ciaccio Ematologia, Catanzaro,Italia, "
        ],
        [
            "Ematologia, Osp. \u201cA. Perrino\u201d, "
        ],
        [
            "Osp. Civile Madonna delle Grazie U.O. Talassemia Matera, Italia, "
        ],
        [
            "Dipartimento di Scienze Statistiche e Matematiche \u2018S. Vianelli\u2019, Universita\u0300 di Palermo, Italia"
        ]
    ],
    "first_author_latitude": "38.1585859",
    "first_author_longitude": "13.3255137",
    "abstract_text": "Abstract 5302 Background: A multicentre randomized controlled trial (RCT) was designed to assess the effectiveness of long-term sequential deferiprone-deferoxamine (DFO-DFP) versus DFP alone to treat thalassaemia major (TM) (Maggio et al.,2009). Effectviness, survival, adverse events and costs were comparable between the groups. These findings were confirmed in a further 21-month follow-up (Pantalone et al., 2011). Moreover, deferiprone-alone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular ejection function (LVEF). However, little is known of its relative effect on LVEF after long-term treatment. Therefore, data from this prospective RCT were retrospectively analyzed to assess the LVEF responses to these treatments. Methods: In this retrospective survey of RCT, 99 patients with TM received, from September 30, 2000 to December 31, 2007, LVEF study consecutively ( Table I ). Generalized Estimating Equations (GEE) model was used to show the possible change of the mean of LVEF over the time between the Sequential DFP-DFO versus the DFP (Hedeker & Gibbons, 2006). This approach was implemented in the 'xtgee' procedure of Stata 11 software (StataCorp, College Station, TX, USA). All of the statistical analyses were performed under code at the Department for Mathematical and Statistical Sciences 'S. Vianelli', University of Palermo (Italy) by A.V. Results: Baseline findings are shown on Table I . Figure 1 shows the pro\u00deles of the GEE model for the change in the mean LVEF between the two groups. The regression coefficient of treatment suggests as, the DFP-group shows statistically significant increase of mean ejection fraction over time (Coeff. 0,97, 95% CI (0,51; 1,44), p-value<0,0001, Fig. I). Actually, while the Sequential DFP-DFO treatment shows a slight advantage in terms of difference in the mean of LVEF (Coeff. 2,36, 95% CI (0,02; 4,71), p-value=0,047,Fig. I), it does not increase significantly LVEF over the time (Coeff. \u22120,34, 95% CI (\u22121,09; 0,39), p-value=0,359). Table I. Baseline findings in the 99 patients included in the retrospective cohort study  Findings . DFP-group . Sequential-group . p-value . N\u00b0 pts (99)  60 39  Females (%)  22 (36,66) 21 (53,84)  Age in years  31\u00b17,52 31\u00b18,66 0,96 Hgb, g/l*  9,24\u00b10,87 9,32\u00b10,68 0,78 ALT, IU/L*  49,73\u00b137,88 38,27\u00b145,97 0,43 LIC, mg/g/dw  2946,03\u00b12026,56 2351,08\u00b12234,03 0,38 Total blood transfusion, ml/kg/year  8716,172\u00b12111,04 8268,02\u00b12561,87 0,34 Mean ferritin, mg/l  1664,21\u00b1846,62 1717,54\u00b1497,79 0,84 Mean basal EF < 55% (n\u00b0)  52\u00b12,19 (6) 50,66\u00b13,05 (3) 0,47 Basal mean ejection fraction  59,25\u00b14,25 60,89\u00b15,78 0,10 Mean age at DFO starting, years  5,75\u00b14,34 5,03\u00b14,61 0,46 Splenectomy (%)  33(55) 27 (69,23) 0,26 Cirrhosis (%)  54 (90,00) 38 (97,43) 0,16 Arrhythmia (%)  49 (81,66) 35 (89,74) 0,31 HCV-RNA positive (%)  42 (70,00) 30 (76,92) 0,51 Findings . DFP-group . Sequential-group . p-value . N\u00b0 pts (99)  60 39  Females (%)  22 (36,66) 21 (53,84)  Age in years  31\u00b17,52 31\u00b18,66 0,96 Hgb, g/l*  9,24\u00b10,87 9,32\u00b10,68 0,78 ALT, IU/L*  49,73\u00b137,88 38,27\u00b145,97 0,43 LIC, mg/g/dw  2946,03\u00b12026,56 2351,08\u00b12234,03 0,38 Total blood transfusion, ml/kg/year  8716,172\u00b12111,04 8268,02\u00b12561,87 0,34 Mean ferritin, mg/l  1664,21\u00b1846,62 1717,54\u00b1497,79 0,84 Mean basal EF < 55% (n\u00b0)  52\u00b12,19 (6) 50,66\u00b13,05 (3) 0,47 Basal mean ejection fraction  59,25\u00b14,25 60,89\u00b15,78 0,10 Mean age at DFO starting, years  5,75\u00b14,34 5,03\u00b14,61 0,46 Splenectomy (%)  33(55) 27 (69,23) 0,26 Cirrhosis (%)  54 (90,00) 38 (97,43) 0,16 Arrhythmia (%)  49 (81,66) 35 (89,74) 0,31 HCV-RNA positive (%)  42 (70,00) 30 (76,92) 0,51 View Large Figure 1. View large Download slide Estimated pro\u00deles from the \u00detted GEE model for the DFP versus the DFP-DFO Sequential-group. Figure 1. View large Download slide Estimated pro\u00deles from the \u00detted GEE model for the DFP versus the DFP-DFO Sequential-group.  Discussion: Previous retrospective studies suggested as deferiprone \u2013treated patients had higher LVEF in comparison with Deferoxamine (DFO) or Deferasirox (DFX) treated groups (Anderson et al., 2002; Pepe et al., 2011). Moreover, survival analysis suggested a substantial decline in cardiac deaths in recent years, related to switching high-risk patients from subcutaneous desferrioxamine to chelation regimes which include the oral chelator deferiprone (Borgna-Pignatti et al., 2006; Telfer et al., 2009). Finally, Pennell et al. 2006 suggested, during a RCT over 1 year comparing DFO versus DFP, as LVEF increased significantly more in the deferiprone-treated group (3.1% vs 0.3% absolute units; P =.003). This retrospective survey of long-term prospective RCT, shows as the effect of deferiprone-alone treatment increases significantly during the years (Coeff. 0,97, 95% CI (0,51; 1,44), p-value<0,0001, Fig. 1 ). Cardioprotective effect of deferiprone on mitochondrial function in cultured, iron-loaded heart cells has been suggested (Link et al., 1999;Glickstein et al., 2006;Xu et al.,2006), even at concentrations below the iron-mobilizing effect (Link et al.,1999). These findings clincally support as long-term treatment with DFP-alone enhances LVEF over the years and may prevent death due to heart failure in patients with thalassemia major. Disclosures: Off Label Use: Deferiprone on sequencial way with Deferoxamine."
}